Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22F3N9O3S |
InChIKeyJHMIVIDGICWPMZ-SRVKXCTJSA-N |
CAS Registry3047323-41-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 30 May 2025 |





